$1.10 Million in Sales Expected for Aptinyx Inc (APTX) This Quarter
Analysts forecast that Aptinyx Inc (NASDAQ:APTX) will post sales of $1.10 million for the current quarter, Zacks reports. Two analysts have provided estimates for Aptinyx’s earnings, with the lowest sales estimate coming in at $1.00 million and the highest estimate coming in at $1.20 million. The company is expected to issue its next quarterly earnings results on Tuesday, November 13th.
On average, analysts expect that Aptinyx will report full-year sales of $6.50 million for the current year, with estimates ranging from $6.00 million to $6.99 million. For the next fiscal year, analysts forecast that the business will post sales of $4.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Aptinyx.
Aptinyx (NASDAQ:APTX) last announced its quarterly earnings results on Tuesday, August 14th. The company reported ($1.83) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($1.35). The company had revenue of $2.13 million during the quarter, compared to the consensus estimate of $2.10 million.
APTX stock traded up $0.01 during trading on Monday, hitting $28.20. 605 shares of the company traded hands, compared to its average volume of 225,629. Aptinyx has a 1 year low of $17.35 and a 1 year high of $32.25.
A number of institutional investors and hedge funds have recently modified their holdings of APTX. Frazier Management LLC acquired a new stake in Aptinyx in the second quarter valued at approximately $77,104,000. Partner Fund Management L.P. acquired a new stake in shares of Aptinyx in the second quarter worth approximately $32,072,000. NF Trinity Capital Hong Kong Ltd acquired a new stake in shares of Aptinyx in the second quarter worth approximately $17,121,000. Victory Capital Management Inc. acquired a new stake in shares of Aptinyx in the second quarter worth approximately $16,984,000. Finally, Laurion Capital Management LP acquired a new stake in shares of Aptinyx in the second quarter worth approximately $6,043,000. 60.09% of the stock is currently owned by institutional investors.
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Further Reading: Momentum Indicator: Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.